Difference in the centrosome duplication regulatory activity among p53 ‘hot spot’ mutants: Potential role of Ser 315 phosphorylation-dependent centrosome binding of p53

Pheruza Tarapore, Yukari Tokuyama, Henning Horn, Kenji Fukasawa

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The p53 tumor suppressor protein regulates centrosome duplication through multiple pathways, and p21waf1/Cip1 (Waf1), a major target of p53's transactivation function, has been shown to be one of the effectors. However, it had been unclear whether the p53's Waf1-independent centrosome duplication regulatory pathways require its transactivation function. In human cancers, specific residues of p53 are mutated at a high frequency. These 'hot spot' mutations abrogate p53's transactivation function. If p53 regulates centrosome duplication in a transactivation-independent manner, different 'hot spot' mutants may regulate centrosome duplication differently. To test this, we examined the effect of two 'hot spot' mutants (R175H and R249S) for their centrosome duplication regulatory activities. We found that R175H lost the ability to regulate centrosome duplication, while R249S partially retained it. Moreover, R249S associates with both unduplicated and duplicated centrosomes similar to wild-type p53, while R175H only associates with duplicated, but not unduplicated centrosomes. Since cyclin-dependent kinase 2 (CDK2) triggers initiation of centrosome duplication, and p53 is phosphorylated on Ser 315 by CDK2, we examined the p53 mutants with a replacement of Ser 315 to Ala (A) and Asp (D), both of which retain the transactivation function. We found that S315D retained a complete centrosome duplication activity, while S315A only partially retained it. Moreover, S315D associates with both unduplicated and duplicated centrosomes, while S315A associates with only duplicated, but not unduplicated centrosomes. Thus, p53 controls the centrosome duplication cycle both in transactivation-dependent and transactivation-independent manners, and the ability to bind to unduplicated centrosomes, which is controlled by phosphorylation on Ser 315, may be important for the overall p53-mediated regulation of centrosome duplication.

Original languageEnglish
Pages (from-to)6851-6863
Number of pages13
JournalOncogene
Volume20
Issue number47
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Centrosome
Phosphorylation
Transcriptional Activation
Cyclin-Dependent Kinase 2
Tumor Suppressor Protein p53
Viperidae

Keywords

  • Cancer
  • CDK2
  • Centrosome duplication
  • p53
  • Phosphorylation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Difference in the centrosome duplication regulatory activity among p53 ‘hot spot’ mutants : Potential role of Ser 315 phosphorylation-dependent centrosome binding of p53. / Tarapore, Pheruza; Tokuyama, Yukari; Horn, Henning; Fukasawa, Kenji.

In: Oncogene, Vol. 20, No. 47, 2001, p. 6851-6863.

Research output: Contribution to journalArticle

@article{753a544ebda44cb991386d73aa5040be,
title = "Difference in the centrosome duplication regulatory activity among p53 ‘hot spot’ mutants: Potential role of Ser 315 phosphorylation-dependent centrosome binding of p53",
abstract = "The p53 tumor suppressor protein regulates centrosome duplication through multiple pathways, and p21waf1/Cip1 (Waf1), a major target of p53's transactivation function, has been shown to be one of the effectors. However, it had been unclear whether the p53's Waf1-independent centrosome duplication regulatory pathways require its transactivation function. In human cancers, specific residues of p53 are mutated at a high frequency. These 'hot spot' mutations abrogate p53's transactivation function. If p53 regulates centrosome duplication in a transactivation-independent manner, different 'hot spot' mutants may regulate centrosome duplication differently. To test this, we examined the effect of two 'hot spot' mutants (R175H and R249S) for their centrosome duplication regulatory activities. We found that R175H lost the ability to regulate centrosome duplication, while R249S partially retained it. Moreover, R249S associates with both unduplicated and duplicated centrosomes similar to wild-type p53, while R175H only associates with duplicated, but not unduplicated centrosomes. Since cyclin-dependent kinase 2 (CDK2) triggers initiation of centrosome duplication, and p53 is phosphorylated on Ser 315 by CDK2, we examined the p53 mutants with a replacement of Ser 315 to Ala (A) and Asp (D), both of which retain the transactivation function. We found that S315D retained a complete centrosome duplication activity, while S315A only partially retained it. Moreover, S315D associates with both unduplicated and duplicated centrosomes, while S315A associates with only duplicated, but not unduplicated centrosomes. Thus, p53 controls the centrosome duplication cycle both in transactivation-dependent and transactivation-independent manners, and the ability to bind to unduplicated centrosomes, which is controlled by phosphorylation on Ser 315, may be important for the overall p53-mediated regulation of centrosome duplication.",
keywords = "Cancer, CDK2, Centrosome duplication, p53, Phosphorylation",
author = "Pheruza Tarapore and Yukari Tokuyama and Henning Horn and Kenji Fukasawa",
year = "2001",
doi = "10.1038/sj.onc.1204848",
language = "English",
volume = "20",
pages = "6851--6863",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "47",

}

TY - JOUR

T1 - Difference in the centrosome duplication regulatory activity among p53 ‘hot spot’ mutants

T2 - Potential role of Ser 315 phosphorylation-dependent centrosome binding of p53

AU - Tarapore, Pheruza

AU - Tokuyama, Yukari

AU - Horn, Henning

AU - Fukasawa, Kenji

PY - 2001

Y1 - 2001

N2 - The p53 tumor suppressor protein regulates centrosome duplication through multiple pathways, and p21waf1/Cip1 (Waf1), a major target of p53's transactivation function, has been shown to be one of the effectors. However, it had been unclear whether the p53's Waf1-independent centrosome duplication regulatory pathways require its transactivation function. In human cancers, specific residues of p53 are mutated at a high frequency. These 'hot spot' mutations abrogate p53's transactivation function. If p53 regulates centrosome duplication in a transactivation-independent manner, different 'hot spot' mutants may regulate centrosome duplication differently. To test this, we examined the effect of two 'hot spot' mutants (R175H and R249S) for their centrosome duplication regulatory activities. We found that R175H lost the ability to regulate centrosome duplication, while R249S partially retained it. Moreover, R249S associates with both unduplicated and duplicated centrosomes similar to wild-type p53, while R175H only associates with duplicated, but not unduplicated centrosomes. Since cyclin-dependent kinase 2 (CDK2) triggers initiation of centrosome duplication, and p53 is phosphorylated on Ser 315 by CDK2, we examined the p53 mutants with a replacement of Ser 315 to Ala (A) and Asp (D), both of which retain the transactivation function. We found that S315D retained a complete centrosome duplication activity, while S315A only partially retained it. Moreover, S315D associates with both unduplicated and duplicated centrosomes, while S315A associates with only duplicated, but not unduplicated centrosomes. Thus, p53 controls the centrosome duplication cycle both in transactivation-dependent and transactivation-independent manners, and the ability to bind to unduplicated centrosomes, which is controlled by phosphorylation on Ser 315, may be important for the overall p53-mediated regulation of centrosome duplication.

AB - The p53 tumor suppressor protein regulates centrosome duplication through multiple pathways, and p21waf1/Cip1 (Waf1), a major target of p53's transactivation function, has been shown to be one of the effectors. However, it had been unclear whether the p53's Waf1-independent centrosome duplication regulatory pathways require its transactivation function. In human cancers, specific residues of p53 are mutated at a high frequency. These 'hot spot' mutations abrogate p53's transactivation function. If p53 regulates centrosome duplication in a transactivation-independent manner, different 'hot spot' mutants may regulate centrosome duplication differently. To test this, we examined the effect of two 'hot spot' mutants (R175H and R249S) for their centrosome duplication regulatory activities. We found that R175H lost the ability to regulate centrosome duplication, while R249S partially retained it. Moreover, R249S associates with both unduplicated and duplicated centrosomes similar to wild-type p53, while R175H only associates with duplicated, but not unduplicated centrosomes. Since cyclin-dependent kinase 2 (CDK2) triggers initiation of centrosome duplication, and p53 is phosphorylated on Ser 315 by CDK2, we examined the p53 mutants with a replacement of Ser 315 to Ala (A) and Asp (D), both of which retain the transactivation function. We found that S315D retained a complete centrosome duplication activity, while S315A only partially retained it. Moreover, S315D associates with both unduplicated and duplicated centrosomes, while S315A associates with only duplicated, but not unduplicated centrosomes. Thus, p53 controls the centrosome duplication cycle both in transactivation-dependent and transactivation-independent manners, and the ability to bind to unduplicated centrosomes, which is controlled by phosphorylation on Ser 315, may be important for the overall p53-mediated regulation of centrosome duplication.

KW - Cancer

KW - CDK2

KW - Centrosome duplication

KW - p53

KW - Phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=0035909514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035909514&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1204848

DO - 10.1038/sj.onc.1204848

M3 - Article

C2 - 11687964

AN - SCOPUS:0035909514

VL - 20

SP - 6851

EP - 6863

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 47

ER -